

Vitamin D shows no impact on interferon response in SLE

10 July 2015



no differences in expression among patients with vitamin D depletion versus those with persistent vitamin D deficiency.

"Vitamin D₃ supplementation up to 4,000 IU daily was safe and well tolerated but failed to diminish the IFN signature in vitamin D-deficient SLE patients," the authors write.

One author is an employee of Rho Federal Systems, a division of Rho, a contract research organization.

More information: [Abstract](#)
[Full Text \(subscription or payment may be required\)](#)

(HealthDay)—For patients with systemic lupus erythematosus (SLE), vitamin D₃ supplementation does not affect interferon (IFN) signature, according to a study published in the July issue of *Arthritis & Rheumatology*.

Copyright © 2015 [HealthDay](#). All rights reserved.

Cynthia Aranow, M.D., from the Feinstein Institute for Medical Research in Manhasset, N.Y., and colleagues examined the effects of [vitamin D](#) supplementation on the IFN signature (expression level of three IFN genes) in 57 patients with stable, inactive SLE. Patients were randomized into a 12-week trial of vitamin D₃ at doses of 2,000 or 4,000 IU, or placebo.

The researchers found that repletion of 25-hydroxyvitamin D (>30 ng/mL) was observed in 16 of the 33 patients receiving vitamin D₃, but in none of the patients receiving placebo. There was no difference between the treatment groups in the percentage of patients with an IFN signature response. Furthermore, the percentage of patients with an IFN signature response did not differ between those who remained vitamin D deficient and those who demonstrated repletion of vitamin D. No changes from baseline were seen in any of the treatment groups in modular microarray analysis of a subset of 40 patients; there were also

APA citation: Vitamin D shows no impact on interferon response in SLE (2015, July 10) retrieved 29 April 2021 from <https://medicalxpress.com/news/2015-07-vitamin-d-impact-interferon-response.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.